These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 34133478)
81. Mechanisms and biomarkers of apoptosis in liver disease and fibrosis. Chakraborty JB; Oakley F; Walsh MJ Int J Hepatol; 2012; 2012():648915. PubMed ID: 22567408 [TBL] [Abstract][Full Text] [Related]
82. Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. Anstee QM; Concas D; Kudo H; Levene A; Pollard J; Charlton P; Thomas HC; Thursz MR; Goldin RD J Hepatol; 2010 Sep; 53(3):542-50. PubMed ID: 20557969 [TBL] [Abstract][Full Text] [Related]
83. Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor - a randomized placebo-controlled study in patients with chronic hepatitis C. Shiffman ML; Pockros P; McHutchison JG; Schiff ER; Morris M; Burgess G Aliment Pharmacol Ther; 2010 May; 31(9):969-78. PubMed ID: 20163376 [TBL] [Abstract][Full Text] [Related]
84. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Witek RP; Stone WC; Karaca FG; Syn WK; Pereira TA; Agboola KM; Omenetti A; Jung Y; Teaberry V; Choi SS; Guy CD; Pollard J; Charlton P; Diehl AM Hepatology; 2009 Nov; 50(5):1421-30. PubMed ID: 19676126 [TBL] [Abstract][Full Text] [Related]
85. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Liberati A; Altman DG; Tetzlaff J; Mulrow C; Gøtzsche PC; Ioannidis JP; Clarke M; Devereaux PJ; Kleijnen J; Moher D PLoS Med; 2009 Jul; 6(7):e1000100. PubMed ID: 19621070 [TBL] [Abstract][Full Text] [Related]
86. Orally-administered caspase inhibitor PF-03491390 is retained in the liver for prolonged periods with low systemic exposure, exerting a hepatoprotective effect against alpha-fas-induced liver injury in a mouse model. Ueno Y; Ohmi T; Yamamoto M; Kato N; Moriguchi Y; Kojima M; Shimozono R; Suzuki S; Matsuura T; Eda H J Pharmacol Sci; 2007 Oct; 105(2):201-5. PubMed ID: 17928737 [TBL] [Abstract][Full Text] [Related]
87. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Pockros PJ; Schiff ER; Shiffman ML; McHutchison JG; Gish RG; Afdhal NH; Makhviladze M; Huyghe M; Hecht D; Oltersdorf T; Shapiro DA Hepatology; 2007 Aug; 46(2):324-9. PubMed ID: 17654603 [TBL] [Abstract][Full Text] [Related]
88. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. Iredale JP J Clin Invest; 2007 Mar; 117(3):539-48. PubMed ID: 17332881 [TBL] [Abstract][Full Text] [Related]
89. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Wieckowska A; Zein NN; Yerian LM; Lopez AR; McCullough AJ; Feldstein AE Hepatology; 2006 Jul; 44(1):27-33. PubMed ID: 16799979 [TBL] [Abstract][Full Text] [Related]
90. Comparison of two methods to detect publication bias in meta-analysis. Peters JL; Sutton AJ; Jones DR; Abrams KR; Rushton L JAMA; 2006 Feb; 295(6):676-80. PubMed ID: 16467236 [TBL] [Abstract][Full Text] [Related]
91. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Bantel H; Lügering A; Heidemann J; Volkmann X; Poremba C; Strassburg CP; Manns MP; Schulze-Osthoff K Hepatology; 2004 Nov; 40(5):1078-87. PubMed ID: 15486927 [TBL] [Abstract][Full Text] [Related]
92. Fibrotic disease and the T(H)1/T(H)2 paradigm. Wynn TA Nat Rev Immunol; 2004 Aug; 4(8):583-94. PubMed ID: 15286725 [TBL] [Abstract][Full Text] [Related]
93. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Kramer G; Erdal H; Mertens HJ; Nap M; Mauermann J; Steiner G; Marberger M; Bivén K; Shoshan MC; Linder S Cancer Res; 2004 Mar; 64(5):1751-6. PubMed ID: 14996736 [TBL] [Abstract][Full Text] [Related]
94. Apoptosis: the nexus of liver injury and fibrosis. Canbay A; Friedman S; Gores GJ Hepatology; 2004 Feb; 39(2):273-8. PubMed ID: 14767974 [No Abstract] [Full Text] [Related]
96. First clinical trial of a novel caspase inhibitor: anti-apoptotic caspase inhibitor, IDN-6556, improves liver enzymes. Valentino KL; Gutierrez M; Sanchez R; Winship MJ; Shapiro DA Int J Clin Pharmacol Ther; 2003 Oct; 41(10):441-9. PubMed ID: 14703949 [TBL] [Abstract][Full Text] [Related]
97. The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. Canbay A; Feldstein A; Baskin-Bey E; Bronk SF; Gores GJ J Pharmacol Exp Ther; 2004 Mar; 308(3):1191-6. PubMed ID: 14617689 [TBL] [Abstract][Full Text] [Related]
98. Fas-mediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption, and may be associated with hepatic fibrosis: mechanisms of liver cell injury in chronic hepatitis C virus infection. Pianko S; Patella S; Ostapowicz G; Desmond P; Sievert W J Viral Hepat; 2001 Nov; 8(6):406-13. PubMed ID: 11703571 [TBL] [Abstract][Full Text] [Related]
99. Bias in meta-analysis detected by a simple, graphical test. Egger M; Davey Smith G; Schneider M; Minder C BMJ; 1997 Sep; 315(7109):629-34. PubMed ID: 9310563 [TBL] [Abstract][Full Text] [Related]
100. Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. Caulín C; Salvesen GS; Oshima RG J Cell Biol; 1997 Sep; 138(6):1379-94. PubMed ID: 9298992 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]